Decoy Therapeutics Secures $3.85 Million in Warrant Inducement Deal

The transaction involves the immediate exercise of 1,184,434 Series B Milestone Warrants at a reduced price of $3.25 per share. In a move to incentivize this capital infusion, Decoy Therapeutics also lowered the exercise price for its outstanding Series A and Series C Milestone Warrants to the same $3.25 threshold. As part of the arrangement, the participating investor will receive new unregistered warrants to purchase up to 2,368,868 additional shares of common stock, pending stockholder approval.

Curvature Securities LLC is serving as the sole placement agent for the offering. The company intends to allocate the net proceeds toward working capital and ongoing research initiatives. Decoy Therapeutics, which focuses on developing its proprietary D-MAV antiviral platform, operates under the oversight of CFO Mark Rosenblun. The securities issued in the private placement remain unregistered under the Securities Act of 1933, though the company has committed to filing a registration statement for the resale of shares resulting from the new warrants.